Food and Drug Administration Information Technology Strategy and Customer Experience Strategy; Request for Comments; Extension of Comment Period, 59738-59739 [2024-16089]

Download as PDF 59738 Federal Register / Vol. 89, No. 141 / Tuesday, July 23, 2024 / Notices Pinnacle Bank, Fort Worth, Texas; Pinnacle Bank-Wyoming, Cody, Wyoming; and Bank of Colorado, Fort Collins, Colorado, and to become a member of the Dinsdale Family Group, a group acting in concert that controls Pinnacle Bancorp, Inc. B. Federal Reserve Bank of Minneapolis (Stephanie Weber, Assistant Vice President), 90 Hennepin Avenue, Minneapolis, Minnesota 55480–0291. Comments can also be sent electronically to MA@mpls.frb.org: 1. Colleen Short Lucke, Edina, Minnesota; Kevin Short, Hudson, Wisconsin; and Elizabeth Short, University Heights, Ohio; each individually and as trustee of one or more Short family trusts; to retain voting shares of 215 Holding Co., Minneapolis, Minnesota (‘‘Company’’), and thereby indirectly retain voting shares of Liberty Financial Services, Inc., and Liberty National Bank, both of Sioux City, Iowa; First Farmers & Merchants National Bank, Luverne, Minnesota; First Farmers & Merchants National Bank, Fairmont, Minnesota; First Farmers & Merchants State Bank, Brownsdale, Minnesota; First Farmers & Merchants State Bank of Grand Meadow, Grand Meadow, Minnesota; and First Farmers & Merchants Bank, Cannon Falls, Minnesota (together ‘‘the Subsidiaries’’). Additionally, the Robert M. Short Revocable Trust, Minneapolis, Minnesota (trustees Brian Short, St. Paul, Minnesota; Marianne Short, St. Paul, Minnesota; and Colleen Short Lucke) to join the Short family shareholder group and to retain voting shares of Company and thereby indirectly retain voting shares of the Subsidiaries. Electronic Submissions DEPARTMENT OF HEALTH AND HUMAN SERVICES Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). Food and Drug Administration Written/Paper Submissions [Docket No. FDA–2024–N–2886] Submit written/paper submissions as follows: • Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked, and Board of Governors of the Federal Reserve System. Erin Cayce, Assistant Secretary of the Board. [FR Doc. 2024–16164 Filed 7–22–24; 8:45 am] BILLING CODE P ddrumheller on DSK120RN23PROD with NOTICES1 The Food and Drug Administration (FDA or the Agency) is extending the comment period for the notice announcing a request for comments that appeared in the Federal Register of June 26, 2024. In the notice, FDA requested comments on its ‘‘Information Technology (IT) Strategy’’ and ‘‘Customer Experience (CX) Strategy.’’ The Agency is taking this action to allow interested persons additional time to submit comments. DATES: FDA is extending the comment period on the notice published June 26, 2024 (89 FR 53425). Submit either electronic or written comments by August 30, 2024, to ensure that the Agency considers your comment on this request for comments before finalizing the strategies. ADDRESSES: You may submit comments as follows: SUMMARY: Food and Drug Administration Information Technology Strategy and Customer Experience Strategy; Request for Comments; Extension of Comment Period AGENCY: Food and Drug Administration, HHS. Notice of availability; extension of comment period. ACTION: VerDate Sep<11>2014 18:47 Jul 22, 2024 Jkt 262001 PO 00000 Frm 00024 Fmt 4703 Sfmt 4703 identified, as confidential, if submitted as detailed in ‘‘Instructions.’’ Instructions: All submissions received must include the Docket No. FDA– 2024–N–2886 for ‘‘FDA IT Strategy and CX Strategy.’’ Received comments will be placed in the docket and, except for those submitted as ‘‘Confidential Submissions,’’ publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500. • Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ‘‘THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.’’ The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ‘‘confidential.’’ Any information marked as ‘‘confidential’’ will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.govinfo. gov/content/pkg/FR-2015-09-18/pdf/ 2015-23389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations. gov and insert the docket number, found in brackets in the heading of this document, into the ‘‘Search’’ box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500. Casi Alexander, Office of Digital Transformation, Food and Drug Administration, FDA Library, 5630 Fishers Lane, Rm. 1087, Rockville, MD 20857, 240–402–5171, email: Casi.Alexander@fda.hhs.gov. FOR FURTHER INFORMATION CONTACT: E:\FR\FM\23JYN1.SGM 23JYN1 Federal Register / Vol. 89, No. 141 / Tuesday, July 23, 2024 / Notices In the Federal Register of June 26, 2024, FDA published a notice announcing a request for comments entitled ‘‘FDA Information Technology Strategy and Customer Experience Strategy; Request for Comments.’’ Interested persons were originally given until July 31, 2024, to comment on the document. The Agency has elected to extend the comment period so that all interested parties are able to consider the request for input more thoroughly. FDA is extending the comment period for 30 days, until August 30, 2024. The Agency believes that this 30-day extension allows adequate time for interested persons to submit comments. SUPPLEMENTARY INFORMATION: Dated: July 17, 2024. Lauren K. Roth, Associate Commissioner for Policy. [FR Doc. 2024–16089 Filed 7–22–24; 8:45 am] Regulations Under the Federal Import Milk Act (FIMA)—21 CFR Part 1210 DEPARTMENT OF HEALTH AND HUMAN SERVICES OMB Control Number 0910–0212— Extension This information collection supports FDA regulations. Under FIMA (21 U.S.C. 141–149), milk or cream may be imported into the United States only by the holder of a valid import milk permit (21 U.S.C. 141). Before such permit is issued: (1) all cows from which import milk or cream is produced must be physically examined and found healthy; (2) if the milk or cream is imported raw, all such cows must pass a tuberculin test; (3) the dairy farm and each plant in which the milk or cream is processed or handled must be inspected and found to meet certain sanitary requirements; (4) bacterial counts of the milk at the time of importation must not exceed specified limits; and (5) the temperature of the milk or cream at time of importation must not exceed 50 °F (21 U.S.C. 142). Our regulations in part 1210 (21 CFR part 1210) implement the provisions of FIMA. Sections 1210.11 and 1210.14 require reports on the sanitary conditions of, respectively, dairy farms and plants producing milk and/or cream to be shipped to the United States. Food and Drug Administration [Docket No. FDA–2024–N–0972] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Regulations Under the Federal Import Milk Act AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. DATES: Submit written comments (including recommendations) on the collection of information by August 22, 2024. ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written SUMMARY: Section 1210.12 requires reports on the physical examination of herds, while § 1210.13 requires the reporting of tuberculin testing of the herds. In addition, the regulations in part 1210 require that dairy farmers and plants maintain pasteurization records (§ 1210.15) and that each container of milk or cream imported into the United States bear a tag with the product type, permit number, and shipper’s name and address (§ 1210.22). Section 1210.20 requires that an application for a permit to ship or transport milk or cream into the United States be made by the actual shipper. Section 1210.23 allows permits to be granted based on certificates from accredited officials. To assist respondents with the regulatory requirements, we have developed the following forms: • Form FDA 1815: Certificate/ Transmittal for an Application (21 CFR 1210.23). • Form FDA 1993: Application for Permit To Ship or Transport Milk and/ or Cream into the United States (21 CFR 1210.20). • Form FDA 1994: Report of Tuberculin Tests of Cattle (21 CFR 1210.13). • Form FDA 1995: Report of Physical Examination of Cows (21 CFR 1210.12). • Form FDA 1996: Dairy Farm Sanitary Report (21 CFR 1210.11). • Form FDA 1997: Score Card for Sanitary Inspection of Milk Plants (21 CFR 1210.14). The information collected is used by FDA to determine whether a permit to import milk and/or cream into the United States should be granted. Description of Respondents: Respondents include foreign dairy farms and plants engaged in transporting milk and/or cream into the United States. Respondents are from the private sector (for-profit businesses). In the Federal Register of March 21, 2024 (89 FR 20221), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received. We estimate the burden of this collection of information as follows: comments be submitted to https:// www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting ‘‘Currently under Review—Open for Public Comments’’ or by using the search function. The OMB control number for this information collection is 0910–0212. Also include the FDA docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Amber Sanford, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–8867, PRAStaff@ fda.hhs.gov. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. BILLING CODE 4164–01–P 59739 ddrumheller on DSK120RN23PROD with NOTICES1 TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1 2 21 CFR section Form FDA number/ description 1210.11 ........ 1996/Sanitary inspection of dairy farms. 1995/Physical examination of cows. 1994/Tuberculin test ............ 1210.12 ........ 1210.13 ........ VerDate Sep<11>2014 18:47 Jul 22, 2024 Jkt 262001 Number of responses per respondent Number of respondents PO 00000 Total annual responses Average burden per response Total hours 1 200 200 1.5 ....................................... 300 1 1 1 0.5 (30 minutes) .................. 1 1 1 1 0.5 (30 minutes) .................. 1 Frm 00025 Fmt 4703 Sfmt 4703 E:\FR\FM\23JYN1.SGM 23JYN1

Agencies

[Federal Register Volume 89, Number 141 (Tuesday, July 23, 2024)]
[Notices]
[Pages 59738-59739]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-16089]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2024-N-2886]


Food and Drug Administration Information Technology Strategy and 
Customer Experience Strategy; Request for Comments; Extension of 
Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability; extension of comment period.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or the Agency) is 
extending the comment period for the notice announcing a request for 
comments that appeared in the Federal Register of June 26, 2024. In the 
notice, FDA requested comments on its ``Information Technology (IT) 
Strategy'' and ``Customer Experience (CX) Strategy.'' The Agency is 
taking this action to allow interested persons additional time to 
submit comments.

DATES: FDA is extending the comment period on the notice published June 
26, 2024 (89 FR 53425). Submit either electronic or written comments by 
August 30, 2024, to ensure that the Agency considers your comment on 
this request for comments before finalizing the strategies.

ADDRESSES: You may submit comments as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper 
submissions): Dockets Management Staff (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets 
Management Staff, FDA will post your comment, as well as any 
attachments, except for information submitted, marked, and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2024-N-2886 for ``FDA IT Strategy and CX Strategy.'' Received 
comments will be placed in the docket and, except for those submitted 
as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. 
and 4 p.m., Monday through Friday, 240-402-7500.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states 
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will 
review this copy, including the claimed confidential information, in 
its consideration of comments. The second copy, which will have the 
claimed confidential information redacted/blacked out, will be 
available for public viewing and posted on https://www.regulations.gov. 
Submit both copies to the Dockets Management Staff. If you do not wish 
your name and contact information to be made publicly available, you 
can provide this information on the cover sheet and not in the body of 
your comments and you must identify this information as 
``confidential.'' Any information marked as ``confidential'' will not 
be disclosed except in accordance with 21 CFR 10.20 and other 
applicable disclosure law. For more information about FDA's posting of 
comments to public dockets, see 80 FR 56469, September 18, 2015, or 
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, 
Rm. 1061, Rockville, MD 20852, 240-402-7500.

FOR FURTHER INFORMATION CONTACT: Casi Alexander, Office of Digital 
Transformation, Food and Drug Administration, FDA Library, 5630 Fishers 
Lane, Rm. 1087, Rockville, MD 20857, 240-402-5171, email: 
[email protected].

[[Page 59739]]


SUPPLEMENTARY INFORMATION: In the Federal Register of June 26, 2024, 
FDA published a notice announcing a request for comments entitled ``FDA 
Information Technology Strategy and Customer Experience Strategy; 
Request for Comments.''
    Interested persons were originally given until July 31, 2024, to 
comment on the document. The Agency has elected to extend the comment 
period so that all interested parties are able to consider the request 
for input more thoroughly. FDA is extending the comment period for 30 
days, until August 30, 2024. The Agency believes that this 30-day 
extension allows adequate time for interested persons to submit 
comments.

    Dated: July 17, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024-16089 Filed 7-22-24; 8:45 am]
BILLING CODE 4164-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.